Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, de Vos FYFL, Lolkema MPJK, Devriese LA, Opdam FL, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema ADR, Beijnen JH, Bernards R, Schellens JHM. van Geel RMJM, et al. Among authors: beijnen jh. Br J Cancer. 2020 Apr;122(8):1166-1174. doi: 10.1038/s41416-020-0776-z. Epub 2020 Mar 9. Br J Cancer. 2020. PMID: 32147669 Free PMC article. Clinical Trial.
Population pharmacokinetics of the novel anticancer agent KRN7000.
Crul M, Mathôt RA, Giaccone G, Punt CA, Rosing H, Hillebrand MX, Ando Y, Nishi N, Tanaka H, Schellens JM, Beijnen JH. Crul M, et al. Among authors: beijnen jh. Cancer Chemother Pharmacol. 2002 Apr;49(4):287-93. doi: 10.1007/s00280-001-0413-3. Epub 2002 Jan 24. Cancer Chemother Pharmacol. 2002. PMID: 11914907 Clinical Trial.
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
van Kesteren C, Twelves C, Bowman A, Hoekman K, López-Lázaro L, Jimeno J, Guzman C, Mathôt RA, Simpson A, Vermorken JB, Smyth J, Schellens JH, Hillebrand MJ, Rosing H, Beijnen JH. van Kesteren C, et al. Among authors: beijnen jh. Anticancer Drugs. 2002 Apr;13(4):381-93. doi: 10.1097/00001813-200204000-00007. Anticancer Drugs. 2002. PMID: 11984084 Clinical Trial.
Acute poisoning after oral intake of a toluene-containing paint thinner.
Malingré MM, Hendrix EA, Schellens JH, Koks CH, Tibben MM, Challa EE, Beijnen JH. Malingré MM, et al. Among authors: beijnen jh. Eur J Pediatr. 2002 Jun;161(6):354-5. doi: 10.1007/s00431-001-0889-1. Epub 2002 Apr 16. Eur J Pediatr. 2002. PMID: 12029459 No abstract available.
Urinary and fecal excretion of topotecan in patients with malignant solid tumours.
Herben VM, Schoemaker nE, Rosing H, van Zomeren DM, ten Bokkel Huinink WW, Dubbelman R, Hearn S, Schellens JH, Beijnen JH. Herben VM, et al. Among authors: beijnen jh. Cancer Chemother Pharmacol. 2002 Jul;50(1):59-64. doi: 10.1007/s00280-002-0454-2. Epub 2002 Apr 5. Cancer Chemother Pharmacol. 2002. PMID: 12111113 Clinical Trial.
1,507 results